Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Melanoma, Stage III
Mucosal Melanoma
Interventions
DRUG:
Ipilimumab (YervoyTM, 50 mg/10 mL solution)
DRUG:
Nivolumab (OpdivoTM, 40 mg/4mL solution)
Sponsor
UNICANCER